<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241315</url>
  </required_header>
  <id_info>
    <org_study_id>OTL-2019-OTL38-007</org_study_id>
    <nct_id>NCT04241315</nct_id>
  </id_info>
  <brief_title>ELUCIDATE: Enabling LUng Cancer IDentification Using folATE Receptor Targeting</brief_title>
  <acronym>Elucidate</acronym>
  <official_title>A Phase 3, Randomized,Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>On Target Laboratories, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinipace Worldwide</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>On Target Laboratories, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, multi-center, single dose, open-label, exploratory study in suspected lung
      cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/PET/MRI or other
      imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near
      Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to
      assess the safety and tolerability of single intravenous doses of OTL38.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically Significant Events (CSE)</measure>
    <time_frame>1 day</time_frame>
    <description>The primary efficacy endpoint is the proportion of patients who demonstrate at least one CSE as a result of utilizing OTL-38 and Near Infrared Imaging.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Near-Infrared Imaging group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Imaging Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients in this arm will receive OTL38 for injection but will not receive intraoperative imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTL38 for Injection</intervention_name>
    <description>Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL</description>
    <arm_group_label>Near-Infrared Imaging group</arm_group_label>
    <arm_group_label>No Imaging Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Near infrared camera imaging system</intervention_name>
    <description>Near infrared camera imaging system</description>
    <arm_group_label>Near-Infrared Imaging group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and Female subjects 18 years of age and older

          2. Have a primary diagnosis, or a high clinical suspicion, of cancer in the lung
             warranting surgery based on CT/PET or other imaging

          3. Are scheduled to undergo surgical thoracoscopy for diagnostic wedge resection followed
             by anatomic lung resection

          4. Female subjects of childbearing potential or less than 2 years postmenopausal agree to
             use an acceptable form of contraception from the time of signing informed consent
             until 30 days after study completion

          5. Ability to understand the requirements of the study, provide written informed consent
             and authorization of use and disclosure of protected health information, and agree to
             abide by the study restrictions and to return for the required assessments

        Exclusion Criteria:

          1. Previous exposure to OTL38

          2. Any medical condition that in the opinion of the investigators could potentially
             jeopardize the safety of the subject

          3. History of anaphylactic reactions to folate, including synthetic folic acid
             (pteroylmonoglutamic acid) and contrast agents containing indocyanine green for near
             infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will
             require evaluation.

          4. History of allergy to any of the components of OTL38, including folic acid

          5. A positive serum pregnancy test at Screening or a positive urine pregnancy test on the
             day of surgery or day of admission for female subjects of childbearing potential

          6. Clinically significant abnormalities on electrocardiogram (ECG) at screening.

          7. Presence of any psychological, familial, sociological condition or geographical
             challenges potentially hampering compliance with the study protocol and follow-up
             schedule

          8. Impaired renal function defined as eGFR&lt; 50 mL/min/1.73m2

          9. Impaired liver function defined as values &gt; 3x the upper limit of normal (ULN) for
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline
             phosphatase (ALP), or &gt;2x ULN for total bilirubin except in subjects with Gilbert's
             syndrome.

         10. Received an investigational agent in another investigational drug or vaccine trial
             within 30 days prior to the administration of study drug

         11. Known sensitivity to fluorescent light
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Singhal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aaron J Blouin</last_name>
    <phone>215-908-5866</phone>
    <email>ablouin@ontargetlabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>617-632-8386</phone>
    </contact>
    <investigator>
      <last_name>Sidharta Gangadharan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <email>BOWMANM3@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Sudish Murthy, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Singhal, MD</last_name>
      <phone>215-615-5864</phone>
      <email>sunil.singhal@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Sunil Singhal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Ward, BSN</last_name>
      <phone>412-647-8583</phone>
      <email>wardj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Interpal Sarkaria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Craig DeDegraaf</last_name>
      <phone>713-563-9155</phone>
      <email>cedegra@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>David Rice, M.B., B.Ch.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraoperative Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

